Core Viewpoint - The report from CMB International indicates that the revenue of CSPC Pharmaceutical Group in the third quarter was 6.62 billion yuan, slightly below expectations, but showed significant improvement compared to the second quarter, with a more pronounced recovery expected in the fourth quarter [1] Revenue and Growth Forecast - The management anticipates a return to positive growth by 2026, driven by key new products such as Mingfule, Irinotecan Liposome, and biosimilars (Omalizumab and the upcoming Pertuzumab) [1] - By 2027, growth expectations are expected to become clearer as the impact of centralized procurement dissipates [1] Research and Development - As the innovative pipeline progresses into late-stage clinical development, R&D expenses are projected to increase rapidly [1] Financial Adjustments - Based on the third-quarter performance and management outlook, the revenue forecasts for 2025 to 2027 have been reduced by 5% to 8%, and net profit forecasts have been lowered by 16% to 21% [1] - The target price has been adjusted to 7.3 HKD, with the company facing both positive catalysts and risks in the short term, leading to a reasonable stock valuation and a "Neutral" rating [1]

TG103、HER2 双抗、白紫II 等新品重磅有望26 年获批上市，贡献收入增量。 EGFR ADC：海内外临床稳步推进，看好重磅出海潜力我们看好EGFR ADC 年内国内+海外积极开启三 期：1）国内临床：积极拓展EGFR 突变二线III 期、联合奥希替尼突变一线Ib 随访中，有望年内III期， 及联合PD-1 野生型一线II 期，头颈鳞癌/食管鳞癌在策划一线三期：2）海外临床进展：NSCLC 经典突 变三线及野生型2L+为重点。我们认为EGFRADC 依旧是海内外从数据质量、入组人数及临床进展均具 备竞争力的ADC管线，看好年底到1H26 出海潜力。 机构：华泰证券 研究员：代雯/沈卢庆/孙茗馨 公司公告，实现1-3Q25 收入198.9 亿元（-12.3%yoy，3Q 收入+3.4%yoy，+5.7%qoq），归母净利润35.1 亿元（-7.1%yoy，3Q 利润+27%yoy）；其中3Q25 利润为9.6 亿元（我们估测近6 亿内生利润）。公司 3Q25 收入重回增长，主因：1）成药业务剔除授权收入降幅缩窄，多美素集采影响逐步消散；2）期内 确认与阿斯利康AI 平台及部分Lp（a）小分子BD 合作的 ...

Investment Rating - The report maintains an investment rating of "Buy" for the company with a target price of HKD 12.75 [7]. Core Views - The company achieved a revenue of RMB 19.89 billion for the first three quarters of 2025, representing a year-over-year decline of 12.3%, but a growth of 3.4% year-over-year in Q3 [1]. - The net profit attributable to the parent company for the first three quarters was RMB 3.51 billion, down 7.1% year-over-year, with Q3 profit showing a significant increase of 27% year-over-year [1]. - The revenue growth in Q3 is attributed to the narrowing decline in the prescription drug business and the gradual dissipation of the impact from centralized procurement [1][2]. - The company is optimistic about the continued market expansion of new products such as Omaguzumab and Mingfule under the backdrop of ongoing market development [1][2]. Summary by Sections Revenue and Profitability - The company reported a revenue of RMB 19.89 billion for 1-3Q25, with Q3 revenue showing a 3.4% year-over-year increase and a 5.7% quarter-over-quarter increase [1]. - The net profit for 1-3Q25 was RMB 3.51 billion, with Q3 profit at RMB 960 million, indicating a strong recovery in profitability [1]. Product Pipeline and Business Development - The report highlights the potential of the EGFR ADC pipeline, with ongoing clinical trials both domestically and internationally, indicating strong competitive advantages [3]. - The company confirmed BD revenue of RMB 1.54 billion in 1-3Q25, with expectations for continued BD opportunities in 2026 [4]. Future Outlook - The company anticipates a return to positive growth in prescription drug revenue by 2026, driven by new product launches and the absence of major products in the latest round of centralized procurement [2]. - The projected net profits for 2025-2027 are RMB 4.55 billion, RMB 4.63 billion, and RMB 5.03 billion respectively, with corresponding EPS estimates of RMB 0.40, RMB 0.40, and RMB 0.44 [5][10].

Investment Rating - The report assigns a "Neutral" rating to the company with a target price of HKD 9.30, indicating a potential downside of 11.6% from the current closing price of HKD 10.51 [2][11]. Core Insights - The company is expected to face continued pressure in Q2 2025 due to centralized procurement and hospital-level medical insurance cost control, but there are optimistic prospects for a recovery in the second half of 2025 and in 2026-2027 as these pressures are expected to ease [2][7]. - The report highlights the company's ongoing research and business development (BD) efforts, which are anticipated to contribute positively to performance, alongside a rebound in the raw materials and functional foods business [2][7]. - The target price has been adjusted upwards to reflect the anticipated recovery and the reasonable current valuation, with positive catalysts and risks already factored into the stock price [2][7]. Financial Forecast Changes - Revenue forecasts for 2025 have been revised down by 1.3% to RMB 29,649 million, with further reductions for 2026 and 2027 [6][14]. - The gross profit for 2025 is projected at RMB 20,161 million, reflecting a slight decrease from previous estimates [6][14]. - The net profit attributable to shareholders for 2025 is now expected to be RMB 5,568 million, an increase of 8.4% from prior forecasts [6][14]. Business Segment Performance - In Q2 2025, the company's pharmaceutical business continued to face challenges, with a 24% year-on-year decline in revenue across almost all therapeutic areas [7]. - The raw materials and functional foods segments showed resilience, with revenues increasing by 12% and 8% year-on-year, respectively [7]. - Management anticipates a revenue growth of over 5% in the second half of 2025 compared to the first half, driven by market expansion and new product launches [7]. Long-term Growth Drivers - The company is focusing on innovative products, particularly in the oncology space, with several key trials expected to progress by the end of the year [7]. - The report emphasizes the importance of BD transactions, with two significant deals expected to close by year-end, which could enhance revenue streams [7]. - The company is actively exploring opportunities in various high-potential areas, including peptide long-acting formulations and mRNA vaccines, which are expected to contribute to future revenue and cash flow [7].

Global Market Dynamics - The report indicates a mixed performance in the A-share market, with active trading in the chip and military sectors, while the Hong Kong market was closed for a holiday, and European markets experienced widespread declines due to trade negotiation concerns [3][9][11] - The U.S. labor market remains stable, with attention on Middle Eastern developments, while international oil prices showed mixed movements, and the dollar index slightly increased [4][27] Economic Indicators - High-frequency data suggests a marginal decline in industrial value-added growth in June, with export growth expected to remain stable compared to May. Infrastructure and manufacturing investments are anticipated to perform well, while real estate sentiment continues to decline [6] - The report highlights that the U.S. Senate passed Trump's tax reform and spending cut bill, and the Eurozone's inflation rate slightly increased to 2% in June [6] Stock Market Insights - The report notes that the U.S. stock market is experiencing a mixed performance, with the Dow Jones rising for four consecutive days, while large tech stocks faced declines. The S&P 500 and Nasdaq both retreated from record highs [9] - In the A-share market, the healthcare sector showed strong performance, while the blockchain concept stocks remained weak. The report emphasizes the rise of innovative drug stocks following supportive measures from health authorities [16][19] Sector Analysis - The report suggests a positive outlook for the U.S. tech sector in the next 6-12 months, driven by fiscal policies and easing trade tensions. Specific sub-sectors such as Robotaxi, Fintech, and AI ASIC are highlighted as areas of focus [8] - The Korean semiconductor and storage industry is noted for strong export performance in June, with expectations for continued robust average selling prices in the second half of 2025 [23] Company-Specific Developments - The report mentions that 和黄医药 (Hutchison China MediTech) is expected to enter a profitable phase with rapid overseas sales growth of its drug 呋喹替尼 (Fruquintinib) and stable domestic sales of 赛沃替尼 (Savolitinib) [14] - 新诺威 (Xinnoway) is highlighted for its promising clinical data on its EGFR ADC product, which shows significant potential for overseas licensing [19]

Investment Rating - The report maintains a neutral rating for the company with a target price of HKD 5.80, indicating a potential upside of 14.6% from the current price of HKD 5.06 [1][2][9]. Core Insights - The company's performance in Q4 2024 was negatively impacted by the procurement of Domperidone, but there is a noticeable improvement in the neurology segment. The raw material drug business continues to face slight pressure. It is anticipated that the impact of Domperidone procurement will stabilize entering 2025, with new product launches expected to drive revenue growth [2][6]. - The current forward P/E ratio is 11 times, with an estimated profit CAGR of 11% from 2024 to 2027, suggesting that the valuation is reasonable with limited upside potential [2][6]. - The company is expected to launch seven new products or indications in 2025, including significant approvals in the U.S. for certain drugs, which will help offset losses from procurement [6][7]. Financial Forecasts - Revenue projections for 2025 are set at RMB 29.6 billion, a slight decrease of 1.0% from previous estimates. The gross profit is forecasted at RMB 20.87 billion, reflecting a 3.8% decline [5][11]. - The net profit for 2025 is estimated at RMB 4.75 billion, down 4.4% from prior forecasts, with a net profit margin of 16.1% [5][11]. - The company anticipates a recovery in revenue for 2025, driven by stabilized inventory levels and the rapid market penetration of new products [6][11]. Stock Performance - The stock has shown a year-to-date change of +5.86%, with a 52-week high of HKD 7.12 and a low of HKD 4.34 [5][11]. - The average daily trading volume is reported at 214.03 million shares, indicating active trading interest [5][11]. Valuation Metrics - The DCF valuation model estimates the equity value at approximately RMB 60.89 billion, translating to a per-share value of HKD 5.80 [7][11]. - The company is currently trading at a P/E ratio of 11 times for 2025, with a PEG ratio of 1.0, suggesting that the stock is fairly valued [6][7].